November 6, 2020 07:42 AM EST

Endo Pharmaceuticals chops 560 jobs to refocus on cellulite drug launch

Nicole DeFeudis

Editor

Less than a month after inking a $658 million deal to buy out BioSpecifics Technologies, Endo Pharmaceuticals is shuttering multiple manufacturing sites and cutting …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Endo Pharmaceuticals chops 560 jobs to refocus on cellulite drug launch

Nicole DeFeudis

Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: To spin off or not to spin off? Galapagos backpedals on separation plans, CEO Paul Stoffels exits early

Bayer starts 2025 by cutting 2,000 jobs as it homes in on year-end rehaul target

Dutch biotech gets $146M for late-stage trials in three metabolic disorders

TIGIT graveyard expands as GSK drops late-stage asset with iTeos

Arcturus to prioritize mRNA therapeutics in bid to boost rare disease programs

UnitedHealth Group CEO Andrew Witty steps down

En­do Phar­ma­ceu­ti­cals chops 560 jobs to re­fo­cus on cel­lulite drug launch

Editor

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Endo Pharmaceuticals chops 560 jobs to refocus on cellulite drug launch